Logo image
Back
Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population
Journal article   Open access   Peer reviewed

Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population

Abdulrahman K Sinno, Mona Saraiya, Trevor D Thompson, Brenda Y Hernandez, Marc T Goodman, Martin Steinau, Charles F Lynch, Wendy Cozen, Maria Sibug Saber, Edward S Peters, …
Obstetrics and gynecology (New York. 1953), Vol.123(4), pp.817-821
04/2014
DOI: 10.1097/AOG.0000000000000171
PMCID: PMC4009490
PMID: 24785610
url
http://doi.org/10.1097/AOG.0000000000000171View
Open Access

Abstract

To describe the human papillomavirus (HPV) genotype distribution in invasive vaginal cancers diagnosed before the introduction of the HPV vaccine and evaluate if survival differed by HPV status. Four population-based registries and three residual tissue repositories provided formalin-fixed, paraffin-embedded tissue from microscopically confirmed primary vaginal cancer cases diagnosed between 1994 and 2005 that were tested by L1 consensus polymerase chain reaction with type-specific hybridization in a central laboratory. Clinical, demographic, and all-cause survival data were assessed by HPV status. Sixty cases of invasive vaginal cancer were included. Human papillomavirus was detected in 75% (45) and 25% (15) were HPV-negative. HPV 16 was most frequently detected (55% [33/60]) followed by HPV 33 (18.3% [11/60]). Only one case was positive for HPV 18 (1.7%) Multiple types were detected in 15% of the cases. Vaginal cancers in women younger than 60 years were more likely to be HPV 16- or HPV 18-positive (HPV 16 and 18) than older women, 77.3% compared with 44.7% (P=.038). The median age at diagnosis was younger in the HPV 16 and 18 (59 years) group compared with other HPV-positive (68 years) and no HPV (77 years) (P=.003). The HPV distribution did not significantly vary by race or ethnicity or place of residence. The 5-year unadjusted all-cause survival was 57.4% for women with HPV-positive vaginal cancers compared with 35.7% among those with HPV-negative tumors (P=.243). Three fourths of all vaginal cancers in the United States had HPV detected, much higher than previously found, and 57% could be prevented by current HPV vaccines.
 Registries Carcinoma, Squamous Cell - genetics Humans Middle Aged Kaplan-Meier Estimate Proportional Hazards Models Vaginal Neoplasms - pathology Genotype Vaginal Neoplasms - virology Human papillomavirus 16 - isolation & purification Alphapapillomavirus - genetics Vaginal Neoplasms - mortality Female Adenocarcinoma - genetics

Details

Metrics

23 Record Views
48 Times Cited - Web of Science
Logo image